Step 1 topics → Psychiatry → Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

SNRIs block both the serotonin transporter (SERT) and norepinephrine transporter (NET), distinguishing them from SSRIs which only hit SERT — and on USMLE Step 1, that dual mechanism is what the exam actually tests. The key players are venlafaxine, duloxetine, and desvenlafaxine. Step 1 hits this topic in two main contexts: matching a drug to a non-psychiatric indication (especially neuropathic pain or fibromyalgia) and identifying the side-effect profile when a vignette describes a patient with new-onset hypertension or tachycardia on an antidepressant. The exam loves to hide the drug in a pain management question rather than a depression question.

The tricky part is that students who know SSRIs well tend to treat SNRIs as just a slightly stronger version — same mechanism, same side effects, just more potent. That's wrong in two important ways. First, the norepinephrine component is mechanistically responsible for the pain indication; serotonin alone doesn't explain why duloxetine works for diabetic peripheral neuropathy. Second, the NE component adds a distinct side-effect signature — hypertension, tachycardia, diaphoresis — that SSRIs don't share. USMLE Step 1 will test whether you can separate these.

Venlafaxine has an additional wrinkle that catches students off guard: its norepinephrine activity is dose-dependent. At low doses it behaves essentially like an SSRI. Only at higher doses does NET inhibition become clinically significant. This means the same drug can have a different side-effect and efficacy profile depending on dose — something the exam can exploit in a vignette by specifying the dose range.

From real student decks
59%have cards covering this topic
46%have mature cards

Common misconceptions

Common mistake
Gap: Unaware that the norepinephrine component of SNRIs underlies their efficacy in neuropathic pain and fibromyalgia
SNRIs (duloxetine, venlafaxine) are effective for neuropathic pain and fibromyalgia because norepinephrine reuptake inhibition enhances descending pain inhibition pathways.
The pain benefit of SNRIs comes specifically from norepinephrine reuptake inhibition, which potentiates descending pain inhibitory pathways in the spinal cord — not from serotonin. This is why pure SSRIs are not used for neuropathic pain or fibromyalgia. When you see duloxetine or venlafaxine prescribed for a pain condition, the NE component is doing that work, and knowing this mechanism is what lets you answer 'why this drug' questions correctly.
Common mistake
Wrong: SNRIs have the same side-effect profile as SSRIs.
Right: SNRIs share SSRI-like side effects but additionally cause norepinephrine-mediated effects including hypertension, tachycardia, and increased sweating, particularly at higher doses.
SSRIs and SNRIs are not interchangeable on side effects. SSRIs only hit SERT, so their side effects are serotonin-mediated. SNRIs add NET inhibition, which increases norepinephrine at adrenergic receptors — producing hypertension, tachycardia, and diaphoresis as distinct adverse effects. If a vignette describes a depressed patient whose blood pressure went up after starting a new antidepressant, think SNRI, not SSRI.
Common mistake
Gap: Unaware that venlafaxine's norepinephrine activity is dose-dependent, making low-dose venlafaxine functionally similar to an SSRI
Venlafaxine exhibits dose-dependent receptor activity: serotonin reuptake inhibition predominates at low doses, while norepinephrine reuptake inhibition becomes significant only at higher doses.
Venlafaxine has a much higher affinity for SERT than NET, so at low doses it preferentially inhibits serotonin reuptake and behaves like an SSRI with minimal NE activity. Only as the dose increases does NET inhibition become pharmacologically meaningful. This is clinically relevant because a patient on low-dose venlafaxine won't get the pain benefit or the hypertension risk — both of which require the NE component that kicks in at higher doses.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know that SNRIs work by blocking both SERT and NET, and understand that this dual mechanism is what makes them effective for neuropathic pain, fibromyalgia, and GAD — not just depression.
  2. Recognize that SNRIs carry all the SSRI-like side effects (GI upset, sexual dysfunction, serotonin syndrome risk) PLUS norepinephrine-mediated effects like hypertension, tachycardia, and increased sweating — especially at higher doses.

Can you avoid these mistakes?

A 52-year-old woman with type 2 diabetes is started on duloxetine for painful diabetic peripheral neuropathy. Which component of duloxetine's mechanism accounts for its efficacy in this condition, and through what pathway?
A patient with depression is switched from sertraline to venlafaxine at a high dose. Two weeks later, his blood pressure is 148/94. What pharmacological mechanism explains this change, and why didn't it occur on sertraline?
A physician prescribes low-dose venlafaxine (37.5 mg/day) for a patient with generalized anxiety disorder. A classmate says this is basically the same as prescribing an SSRI. Are they right? What changes if the dose is increased to 225 mg/day?
A vignette describes a patient on an antidepressant who develops serotonin syndrome after adding a triptan. Could this patient be on an SNRI? What additional side effect, unrelated to serotonin syndrome, would you watch for in a patient on high-dose SNRIs that you would not expect in a patient on an SSRI?

Related topics

Selective Serotonin Reuptake Inhibitors (SSRIs) Major Depressive Disorder (MDD) Persistent Depressive Disorder (Dysthymia) Bipolar I Disorder Bipolar II Disorder

See how your Anki deck covers this topic.

Upload your deck for a free audit →